A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer
Crossref DOI link: https://doi.org/10.1007/s10549-015-3675-x
Published Online: 2016-01-09
Published Print: 2016-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Blum, Joanne L.
Gonçalves, Anthony
Efrat, Noa
Debled, Marc
Conte, Pierfranco
Richards, Paul D.
Richards, Donald
Lardelli, Pilar
Nieto, Antonio
Cullell-Young, Martin
Delaloge, Suzette
Text and Data Mining valid from 2016-01-01